Please assess the completion status of the following clinical trial:

Trial Title: Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants based on medical history and clinical assessment.~* Between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.~* Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.~* Subjects must have been born full-term, have a weight-to-height Z score of ≥ -2 at the time of enrollment (WHO child growth standard), and be ≥ 3.5 kg at randomization.~* Subject's parents must be available for the duration of trial participation~Exclusion Criteria:~* Use of any investigational medicinal product prior to randomization.~* Previous vaccination against or infection with S. pneumoniae.~* History of anaphylactic shock or an allergic reaction to any prior vaccination.~* Any fever, illness (including malaria).~* Receipt of another study vaccine within 30 days of study start.~* Chronic administration of an immunosuppressant or administration of immunoglobulins~* History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died suddenly without apparent cause.~* History of meningitis, seizures or any neurological disorder.~* Exposure to human immunodeficiency virus (HIV) by history.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 56 Days
- Healthy Volunteers: t

Study Arms:
- Pneumosil (Type: EXPERIMENTAL): Infants received two primary vaccinations with Pneumosil, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
- Synflorix (Type: ACTIVE_COMPARATOR): Infants received two primary vaccinations with Synflorix, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
- Prevenar 13 (Type: ACTIVE_COMPARATOR): Infants received two primary vaccinations with Prevenar 13, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).